プラシノスタットは,miR-381-3p/ MDM2軸を標的とし,p53信号経路を活性化することで,臓がんの悪質な生物学的行動を抑制する
Dongyun Cun1, Feng Liu1, DaGuang Tian1
1Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital of Kunming Medical University, China.
Pathology, research and practice
|August 28, 2025
まとめ
アセチラーゼ阻害剤であるプラシノスタットは,MDM2を抑制しながら,miR- 381 - 3pとp53を上調することで,臓がんの成長を抑制する. このメカニズムは癌細胞の増殖と移動を阻害し 治療戦略の可能性を秘めています
科学分野:
- 腫瘍学
- 分子生物学
- 癌 研究
背景:
- 臓がんは 予後が悪い 非常に攻撃的な悪性腫瘍です
- アセチラーゼ阻害剤であるプラシノスタットは,様々ながんの抗腫瘍効果を示しています.
- 効果的な治療法の開発には,臓がんにおけるプラシノスタットの分子メカニズムを理解することが不可欠です.
研究 の 目的:
- 臓がん細胞系BxPC3に対するPracinostatの効果を調査する.
- 臓がんにおけるPracinostatの作用の分子メカニズムを解明する.
- プラシノスタットの治療の可能性を in vitro と in vivo で評価する.
主な方法:
- BxPC3細胞はプラチノスタットで治療され,生存性はCCK-8アッセイを用いて評価された.
- miR-381-3pを主要標的として選択した,差異的に発現するmiRNAを特定した.
- 分子相互作用は,デュアルルシフェラーゼレポーターアッセイ,免疫プレシピテーション,およびウェスタン・ブロッティングを用いて検証された. in vivoの有効性はマウスモデルで試験された.
主要な成果:
- プラチノスタット治療は,miR- 381 - 3pとp53の発現を増加させ,MDM2発現を減少させた.
- 臓がん細胞の増殖と移動を抑制し,アポトーシスを誘発した.
- MDM2は,ユビキチン- プロテアソーム経路を通じてp53のユビキチン化と分解を促進することが確認された. 腫瘍の増殖抑制を in vivo 研究で確認した.
結論:
- プラチノスタットは,miR- 381 - 3p/ MDM2軸を調節することによって,p53信号経路を活性化します.
- この活性化により,臓がん細胞の増殖が効果的に抑制されます.
- この発見は,プラシノスタットが臓がんおよび潜在的に他の悪性腫瘍に対する有望な治療薬であることを示唆しています.
関連する概念動画
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Interactions Between Signaling Pathways
6.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K
The Intrinsic Apoptotic Pathway
6.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.8K


